Keywordsandrogen receptor; breast cancer; selective androgen receptor modulator (SARM); estrogen receptor; triple-negative breast cancer (TNBC); triple-negative breast cancer; androgen receptor; prognostic marker; individualized treatment; intrinsic subtype; prostate cancer; breast cancer; bladder cancer; renal cell carcinoma; pancreatic cancer; ovarian cancer; hepatocellular cancer; ovarian cancer; endometrial cancer; androgen receptor; epigenetics; prostate cancer; androgen receptor; methylation; acetylation; non-coding RNA; biomarkers; novel treatments; prostate cancer; stroma; fibroblasts; androgen; androgen receptor; androgen receptor; AR; WNT; prostate; prostate cancer; castration-resistant prostate cancer; CRPC; mammary gland; breast cancer; salivary gland cancer; androgen receptor; salivary duct carcinoma; androgen-deprivation therapy (ADT); androgen; androgen receptor; anti-androgen; carcinogenesis; tumor progression; urothelial cancer; AR signaling; AR/PARP interplay; AR/BET interplay; breast cancer; androgen receptor; androgen receptor signaling pathway; coregulator; octamer transcription factor 1; pyrrole-imidazole polyamide; androgen receptor; AR; VEGF; angiogenesis; hypoxia; prostate cancer; CRPC; PI3K; prostate cancer; AR signaling; castrate resistant prostate cancer; androgen receptor; hepatocellular carcinoma; sorafenib; n/a
